The use of atazanavir (ATV) without the concomitant administration of ritonavir (RTV) as a booster is licensed in the US but not in Europe [1] . Further to the lower pharmacokinetic (PK) exposure of unboosted ATV when compared to RTV-boosted ATV [2] , an additional discouraging factor is represented by the contraindication to tenofovir disoproxil fumarate (TDF) coadministration due to reduction in ATV exposure that takes place when coadministered with the latter [3] . However, the interest around the possibility of administering ATV without RTV is increasing after the release of the results of the INDUMA study [4] . In the INDUMA study, the patients who switched to ATV 400 mg once daily had an immunovirological outcome comparable to those who continued ATV/RTV 300/100 mg once daily after a common induction phase. Moreover, some metabolic parameters improved in the RTV-free arm as compared to controls. More recently, data from the ARIES study [5] confirmed the 48-week efficacy of such an inductionmaintenance strategy. It is noteworthy that in both these trials TDF use in the backbone was not allowed.
The use of atazanavir (ATV) without the concomitant administration of ritonavir (RTV) as a booster is licensed in the US but not in Europe [1] . Further to the lower pharmacokinetic (PK) exposure of unboosted ATV when compared to RTV-boosted ATV [2] , an additional discouraging factor is represented by the contraindication to tenofovir disoproxil fumarate (TDF) coadministration due to reduction in ATV exposure that takes place when coadministered with the latter [3] . However, the interest around the possibility of administering ATV without RTV is increasing after the release of the results of the INDUMA study [4] . In the INDUMA study, the patients who switched to ATV 400 mg once daily had an immunovirological outcome comparable to those who continued ATV/RTV 300/100 mg once daily after a common induction phase. Moreover, some metabolic parameters improved in the RTV-free arm as compared to controls. More recently, data from the ARIES study [5] confirmed the 48-week efficacy of such an inductionmaintenance strategy. It is noteworthy that in both these trials TDF use in the backbone was not allowed.
In clinical practice, regardless of the fact that unboosted ATV is not licensed, a sizeable proportion of ATV intakers in Italy are administered the drug without RTV. For instance, a recent analysis of the SCOLTA cohort [6] showed that 25% of ATV prescriptions are as unboosted. Moreover, despite guideline recommendations, a TDF-containing backbone is administered
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Pharmacokinetics of switching unboosted atazanavir coadministered with tenofovir disoproxil fumarate from 400 mg once daily to 200 mg twice daily in HIV-positive patients Introduction in up to 60% of these patients. This off-label strategy could be very attractive in the clinical practice due to tolerability and convenience [4] [5] [6] in patients with intolerance or contraindications to RTV boosting, nonnucleoside reverse transcriptase inhibitors (NNRTIs) and/or abacavir use. Unfortunately, there is a substantial lack of long-term efficacy data of this approach in the clinical setting.
Since several reports have showed that the PK exposure of unboosted-ATV may be suboptimal in a proportion of patients approaching 50% [7] [8] [9] , it is not clear whether such use of ATV may guarantee the same long-term therapeutic performance that is expected with RTV-boosted protease inhibitors (PIs), particularly when dosed with a TDF-containing backbone.
A possible, yet unexplored, option to improve the PK exposure of ATV and to increase the likelihood of achieving an observed concentration at the end of dosing interval (C trough ) above the recommended threshold of 150 ng/ml is that of splitting the once-daily 400 mg dose into two daily 200 mg doses.
We studied the plasma and intracellular PK of ATV in virologically suppressed patients (<50 HIV RNA copies/ml) under treatment with ATV 400 mg once daily and a TDF-containing backbone who switched to ATV 200 mg twice daily while maintaining the backbone.
Methods
A total of 10 HIV-positive patients (5 males) administered with ATV 400 mg + TDF/emtricitabine (FTC) fixed-dose combination once daily since at least 3 months were enrolled. Patients had no previous history of virological failure to PIs, and they were previously switched to such a regimen because of intolerance to both NNRTI-and RTV-based regimens and potential contraindications to abacavir use. This was a pilot PK study and 10 patients were considered sufficient for relevant conclusions. Local Institutional Review Board approval was obtained and subjects provided written informed consent prior to participation. Inclusion criteria were: HIV RNA<50 copies/ml since at least 6 months, CD4 + T-cell count >300 cells/ ml, self-reported compliance >95%, no hepatic coinfections or other HIV-or non-HIV-related diseases and no administration of concomitant potentially interacting drug (except for TDF). On day 0, subjects administered with ATV 400 mg and TDF/FTC once daily as morning doses underwent intensive total bilirubin measurement and PK evaluation. Blood samples were obtained at the end of dosing interval (T0) and at 2, 4, 8, 12 and 24 h after morning doses. Patients were subsequently switched to continue TDF/FTC once daily in the morning and to take ATV 200 mg twice daily for 10 days. On day 11, patients once again underwent intensive total bilirubin measurement and PK evaluation at T0 and 2, 4, 8 and 12 h after morning doses. After day 11, patients returned to previous standard ATV 400 once daily dosing.
ATV plasma concentrations were measured by HPLC-UV/PDA-validated method using a solid-phase extraction procedure. Chromatographic separation of ATV and the internal standard was achieved with a gradient (acetonitrile and phosphate buffer) on a Luna 150×4.6 (5 micron) C-18 reverse-phase column with a 28 min run time. ATV was detected at 284 nm [10] .
ATV intracellular concentrations were measured by peripheral blood mononuclear cells (PBMCs) extraction procedure (modified from [11] ) followed by HPLC-MS analysis (modified from [12] ). Briefly, PBMCs were isolated by Ficoll, washed using pre-chilled phosphatebuffered saline solutions, and the centrifuge was maintained at 4°C to prevent active drug efflux. The number and median volume of PBMCs (femtolitre) were calculated for each patient by PBMC counter (Z2™ Coulter Counter ® ; Beckman Coulter, Hialeah, FL, USA) and cellular volume was used to correct the ATV HPLC-MS quantification. A chromatographic run was performed with a gradient (HPLC grade water +0.05% formic acid and HPLC grade acetonitrile +0.05% formic acid) on an Atlantis T3 Column 150×2.1 (3 micron), and ATV was detected at 705.40 m/z in positive ion-mode. Both methods for plasmatic and intracellular quantification of ATV were validated following FDA guidelines and both precision (intraday and interday) and accuracy were below the suggested values (<15%).
PK plasma and intracellular parameters were calculated with a non-compartimental model by WinNonlin ® software (version 5.2; Pharsight Corporation, Mountain View, CA, USA) and expressed as geometric means (95% CI). Due to bicompartimental kinetics of unboosted ATV [13] , half-life was calculated by considering both overall elimination phases and only α-elimination phases (4-12 h after administration) of two regimens. Wilcoxon signed rank-sum test and geometric means ratio (95% CI) were used for intraindividual comparison of PK parameters (statistical significance if P<0.05 and 95% CI not including 1, respectively). Correlation between plasma and intracellular concentrations was analysed by Spearman's test. Concentration values were expressed as ng/ml. In Table 1 , comparative evaluation of geometric means of PK parameters and bilirubin levels between ATV 400 mg once daily and 200 mg twice dosing are reported.
Results
Switch to the latter led in plasma to a significant increase of C trough value (305 versus 138 ng/ml, ratio twice daily/ once daily 2.20; P=0.005), a significant decrease of maximum concentration (C max ) value (1,314 versus 2,786 ng/ ml, ratio twice daily/once daily 0.47; P=0.022), whereas no difference in α-elimination half-life was observed (4.25 versus 3.86 h, ratio twice daily/once daily 1.09; P=0.169) and the other PK parameters were similarly unaffected. Plasma concentration-time curves of both ATV dosing regimens are showed in Figure 1 (solid lines). Intraindividual variation of C trough , considered as observed concentration at the end of dosing interval (C 24h and C 12h of intensive PK evaluations) showed that switch to twice daily dosing was associated with a decrease from 60% to 20% of values below the minimum effective concentration (150 ng/ml), bilirubin level at ATV C trough and bilirubin area under the curve (AUC) were slightly higher in 200 mg twice regimen (Table 1) , although these differences were not significant (P=0.05 and P=0.069, respectively). No difference in maximum bilirubin level throughout the dosing interval was observed between ATV regimens (P=0.425).
Geometric means of intracellular PK parameters at ATV 400 once daily dosing showed higher C trough (397 versus 138 ng/ml, ratio PBMCs/plasma 2.86; P=0.005) and longer overall half-life (8.19 versus 5.68 ng/ml, ratio PBMCs/plasma 1.44; P=0.007) as compared to plasma exposure (Table 2 and Figure 1 ), whereas C max and AUC were not significantly affected (Table 2) . Switching from 400 mg once daily to 200 mg twice daily dosing led in the intracellular compartment to similar but not identical changes of drug exposure observed at the plasma level. As reported in Table 3 , a significant increase of C trough value (geometric mean 745 versus 397 ng/ml, ratio twice daily/once daily 1.87; P=0.047), a not significant trend toward decrease of C max (geometric mean 2,104 versus 3,819 ng/ml, ratio twice daily/once daily 0.55; P=0.114) and a substantial equivalence of AUC (geometric mean 31,029 versus 32,287 ng/ml•h ratio twice daily/once daily 0.96; P=0.87) were observed. Moreover, no difference in α-elimination phase half-lives (ratio twice daily/once daily 1.45; P=0.59) was observed.
At 200 mg twice daily dosing, ATV intracellular accumulation was more marked as compared to 400 mg once daily dosing (Table 2 ). In fact, not only higher C trough (geometric mean 745 versus 305 ng/ml, ratio PBMCs/plasma 2.43; P=0.007) and longer overall half-life (geomeric mean 6.17 versus 4.25 h, ratio PBMCs/plasma 1.45; P=0.005) were detected, but also higher C max and AUC were observed (geometric mean 2,104 versus 1,314 ng/ml, ratio PBMCs/plasma 1.60; Wilcoxon signed rank-sum test. ATV, atazanavir; AUC, area under the curve; Cl/F, oral clearance; C max , maximum concentration observed; C trough , concentration at the end of dosing interval (C 24h for once daily and C 12h for twice daily); T ½ , half-life; V/d, volume of distribution. At clinical follow-up at 6 months after the end of the study, no patients experienced any virological breakthrough or CD4 + T-cell decline.
Discussion
Although most of the current worldwide use of ATV is in association with RTV as booster, the interest around the possibility of administering ATV without RTV is increasing after the release of the results of INDUMA [4] and ARIES [5] studies. In the former, patients who switched to ATV 400 mg once daily regimen, with TDF not allowed in the backbone, had an immunovirological outcome comparable to those who continued ATV/RTV 300/100 mg once daily after a common induction phase. Moreover, some metabolic parameters improved in the RTV-free arm as compared to controls, which makes this option even more appealing. In a similar way, the ARIES study evaluated such induction-maintenance strategy with fixed formulation abacavir/3TC as a backbone. At 48 weeks, efficacy analyses confirmed non-inferiority of unboosted maintenance arm, even in patients with baseline HIV RNA>100,000 copies/ml.
The key open question here is whether, despite the overall good short-term therapeutic performance of unboosted ATV in some clinical series and trials [7] [8] [9] 14] , the suboptimal ATV PK exposure measured in different unboosted ATV recipients [2, [7] [8] [9] is of any relevance for the long-term therapeutic performance. Moreover, feasibility of association of unboosted ATV with TDF has not been yet explored in any trials, although the limited observational data available [6] have shown that this is an attractive option frequently used as an off-label strategy in many clinical settings.
In order to further explore this issue and to possibly provide an additional alternative to unboosted ATV intakers, we investigated the plasma and intracellular PK of ATV when administered as single 400 mg once daily dose and after switching to the twice-daily dosing of 200 mg, in 10 virologically suppressed patients receiving unboosted ATV (400 mg once daily) with TDF/FTC.
As expected from prior studies [7] [8] [9] , 6 out of these 10 virologically suppressed patients had plasma ATV C trough below the threshold of 150 ng/ml. Following the switch to ATV 200 mg twice daily, the C trough was observed to be above this cutoff concentration in 8 of 10 patients. As shown in Table 1 and Figure 1 , plasma C trough of ATV after switching from 400 mg once daily to 200 mg twice daily increased significantly, with a ratio of 2.20 (P=0.005). Looking at other parameters of PK exposure, the only difference of statistical significance was the decrease of C max (ratio twice daily/once daily 0.47; P=0.022), whereas the other PK parameters were found to be substantially Wilcoxon signed rank-sum test. ATV, atazanavir; AUC, area under the curve; C max , maximum concentration observed; C trough , concentration at the end of dosing interval (C 24h for once daily and C 12h for twice daily); PBMCs, peripheral blood mononuclear cells; T ½ , half-life.
unchanged. Among these, no difference of half-life was observed when α-elimination phase of the two regimens was considered. Time-concentration curve of 400 mg once daily ATV, in fact, shows a bicompartimental pattern [13] , involving an initial distribution phase, with a rapid α-elimination phase from plasma to body compartments (approximately 4-12 h after administration), followed by a slower β-elimination phase (approximately 12-24 h). When ATV is administered as 200 mg twice daily, the β-elimination phase is not clearly evident (Figure 1) , and the α-elimination phase can be assumed to cover the whole drug elimination phase. Therefore, comparison between α-elimination phases of two regimens seemed appropriate to investigate elimination half-life.
After switch to 200 mg twice daily, total bilirubin measured at ATV C trough showed a trend toward increase (ratio twice daily/once daily 1.31; P=0.05), as it was for total bilirubin exposure throughout the dosing interval (AUC, ratio twice daily/once daily 1.15; P=0.069), whereas no change was observed for maximum bilirubin concentration observed (Table 1) . This is consistent with previous findings that showed that ATV C trough and not C max or AUC was the PK driven force of ATV-related unconjugated hyperbilirubinaemia [15] . It is noteworthy, however, that after-switch increase of total bilirubin at ATV C trough was minimal (1.28-1.78 mg/dl; Table 1), with no clinical impact. In fact, no subjects complained of scleral icterus or jaundice, including the two patients with total bilirubin >2.5 mg/dl at 400 mg once daily dosing, who remained the only two subjects showing bilirubin above such cutoff also after switch to 200 mg twice daily.
Given that RTV-boosted is the ideal regimen with TDF [3] , we could state that in intakers of unboosted ATV plus TDF switching to 200 mg twice daily appeared to optimize ATV PK by increasing the main determinant of efficacy (C trough ) [16] , and decreasing C max , without significant impact under a clinical view point on total ATV plasma exposure and related bilirubin levels. By referring to the threshold value of 150 ng/ml [3] , the magnitude of the C trough increase achieved by the twice-daily dosing seems large enough to move a sizeable proportion of unboosted ATV intakers toward a safer concentration interval, in which the likelihood of virological failure should be lower. As a consequence, from a pure PK perspective, switching from ATV 400 mg once daily to 200 mg twice daily might be a suitable option for those patients who are found to have a suboptimal C trough value. This could potentially optimize the management of therapeutical scenarios otherwise crucial for unboosted ATV, including coadministrationn of interacting drugs other than TDF (that is, proton pump inhibitors) [17] , possibly by relying on therapeutic drug monitoring. However, virological efficacy and impact on adherence of switching from a once daily to a twice daily regimen are unproven and should be assessed in clinical studies.
The study of intracellular PK exposure of ATV 400 mg once daily gave evidence of a higher exposure as compared to plasma PK parameters at the end of dosing interval. The ratio between PBMCs and plasma for ATV 400 mg once daily were 2.86 (P=0.005) for C trough , and 1.44 (P=0.007) for elimination half-life, although C max and AUC values ( Table 2 and Figure 1) were equivalent. In the intracellular compartment, switching to ATV 200 mg had a similar impact to that observed in plasma, although with a lower magnitude ( Table 3) .
In any case, switch to 200 mg twice daily led to an optimization of ATV exposure also at an intracellular level. PBMC-associated drug concentrations measured with this dosing schedule, in fact, were significanly higher as compared to plasma levels not only as a C trough , but throughout the whole dosing interval ( Figure 1 ) and for all the PK parameters investigated (Table 2 ). This more stable intracellular PK profile is witnessed also by the finding that only at 200 mg twice daily dosing was a correlation between plasma and cellular ATV concentration was found.
These data are rather new, since prior knowledge was limited to the analysis of boosted ATV recipients [18, 19] . The question here is whether the concentration values measured at the intracellular level are more or less predictive of drug efficacy than the conventional plasma measurements. In case of PIs, most clinical pharmacological studies have shown good correlation between plasma drug exposure and both efficacy and, to a lesser extent, toxicity [16] , and a series of reference plasma drug levels have been established in order to monitor and guide antiretroviral therapy [3] . This implies that the threshold concentration for ATV efficacy might not be applicable in case of intracellular drug levels, since no studies showing correlation with clinical findings are available. From a more general view point, however, we should not forget that, in case of drugs acting intracellularly, plasma levels are only a surrogate measure of intracellular concentrations. This might account for the good therapeutic response to ATV seen even in patients with suboptimal plasma C trough values. Whatever the ultimate significance of intracellular ATV PK, the results shown here deserve to be challenged on a clinical ground.
In conclusion, the PK profile of ATV when administered at the twice daily dosage of 200 mg might provide a booster-free option for patients whose unboosted ATV PK does not meet the currently adopted requirements.
